The abstract is read at the publisher; the summary is JClub's.
Cannabidiol isolate at 10 mg/kg/d for 8 weeks did not reduce parent-rated ABC-I irritability scores versus placebo in Australian youths with intellectual disability, with a mean difference of 2.4 (95% CI, -1.5 to 6.3).
- Why it matters: Interest in CBD for severe behavioral problems in children with intellectual disability is high, but evidence is limited, creating a need for rigorous randomized trial data to guide clinical practice.
- What they did: In a double-blind, placebo-controlled randomized clinical trial (May 11, 2021–May 8, 2025) at 3 children’s hospitals in Australia, participants aged 6–18 with intellectual disability and severe behavioral problems received CBD isolate in oil (10 mg/kg/d) or placebo for 8 weeks, with a 4-week follow-up.
- The result: Intention-to-treat analysis showed similar end-of-treatment ABC-I subscale scores (21.7 [11.0] for CBD vs 19.2 [10.7] for placebo), and adverse events occurred in 63.1% vs 60.6%, implying CBD should not be used for this indication in this population.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.